These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25820046)

  • 1. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
    Shetty SR; Kumar S; Mathur RP; Sharma KH; Jaiswal AD
    Indian Heart J; 2015; 67(1):23-6. PubMed ID: 25820046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
    Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
    Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
    Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
    Joshi SR
    Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
    Jani RH; Pai V; Jha P; Jariwala G; Mukhopadhyay S; Bhansali A; Joshi S
    Diabetes Technol Ther; 2014 Feb; 16(2):63-71. PubMed ID: 24138536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
    Chatterjee S; Majumder A; Ray S
    Sci Rep; 2015 Jan; 5():7706. PubMed ID: 25573251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first approved agent in the Glitazar's Class: Saroglitazar.
    Agrawal R
    Curr Drug Targets; 2014 Feb; 15(2):151-5. PubMed ID: 23906191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
    Bhosle D; Bhosle V; Bobde J; Bhagat A; Shaikh H; Kadam R
    J Assoc Physicians India; 2018 Mar; 66(3):14-7. PubMed ID: 30341861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Rastogi A; Dunbar RL; Thacker HP; Bhatt J; Parmar K; Parmar DV
    Acta Diabetol; 2020 Jul; 57(7):809-818. PubMed ID: 32030508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
    Rajesh NA; Drishya L; Ambati MMR; Narayanan AL; Alex M; R KK; Abraham JJ; Vijayakumar TM
    J Clin Exp Hepatol; 2022; 12(1):61-67. PubMed ID: 35068786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
    Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
    Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
    Jain N; Bhansali S; Kurpad AV; Hawkins M; Sharma A; Kaur S; Rastogi A; Bhansali A
    Sci Rep; 2019 Dec; 9(1):19017. PubMed ID: 31831868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
    Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.
    Balakumar P; Mahadevan N; Sambathkumar R
    Curr Mol Pharmacol; 2019; 12(3):195-201. PubMed ID: 30636619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
    Deshpande A; Toshniwal H; Joshi S; Jani RH
    PLoS One; 2016; 11(1):e0146222. PubMed ID: 26789842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience.
    Roy S
    Case Rep Med; 2020; 2020():4287075. PubMed ID: 32280349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis.
    Dutta D; Bhattacharya S; Surana V; Aggarwal S; Singla R; Khandelwal D; Sharma M
    Diabetes Metab Syndr; 2020; 14(6):1759-1768. PubMed ID: 32937280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).
    Pai V; Paneerselvam A; Mukhopadhyay S; Bhansali A; Kamath D; Shankar V; Gambhire D; Jani RH; Joshi S; Patel P
    J Diabetes Sci Technol; 2014 Jan; 8(1):132-141. PubMed ID: 24876549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Mitra A
    Cureus; 2020 Jul; 12(7):e9065. PubMed ID: 32782883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.